Company: SXTPW
Filing Date: 2025-02-06
Form Type: 424B5
Source: 0001213900-25-010772
Chunk: 30

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-06
Form: 424B5
Chunk 30
---
 prospectus supplement dated January 28, 2025, filed with the SEC on January 30, 2025, and accompanying base prospectus, pursuant
to Rule 424(b)(5) promulgated under the Securities Act of 1933, as amended (the “Securities Act”).

In a concurrent private placement, the Company
also issued to the Purchasers unregistered warrants (the “Common Warrants”) to purchase up to an aggregate of 2,043,098 shares
(the “Common Warrant Shares”) of common stock at an exercise price of $0.771 per share. The Common Warrants are exercisable
upon issuance and expire twenty-four months from the date of issuance.

Pursuant to the Securities Purchase Agreement,
the Company is required to file a registration statement with the SEC within 45 days after the date of the Securities Purchase Agreement
to register the Warrant Shares under the Securities Act. The Company shall use commercially reasonable efforts to cause such registration
statement to become effective within 75 days following the Closing Date and to keep such registration statement effective at all times
until no Purchaser owns any Common Warrants or Warrant Shares issuable upon exercise thereof.

Any holder will not have the right to exercise
any portion of the Common Warrants if the holder (together with its affiliates) would beneficially own more than 4.99% (or, upon the election
of the holder, 9.99%) of the number of shares of the common stock outstanding immediately after giving effect to the exercise, as such
percentage ownership is determined in accordance with the terms of the Common Warrants. However, any holder may increase or decrease such
percentage, provided that any increase will not be effective until the 61st day after such election.

The exercise price of the Common Warrants is subject
to customary adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications
or similar events affecting the common stock and also upon any distributions of assets, including cash, stock or other property to the
stockholders of the Company.

The issuance of the Common Warrants pursuant to
the Securities Purchase Agreement and issuance of warrants to the Placement Agent (the “Placement Agent Warrants”) were made
pursuant to the exemption from the registration requirements under the Securities Act, available to the Company under Section 4(a)(2)
promulgated thereunder and Rule 506 of Regulation D promulgated under the Securities Act due to the